Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction

Patent metadata

Field	Value
Publication number	US-11285151-B2
Application number	US-201916549226-A
Country	US
Kind code	B2
Filing date	Aug 23, 2019
Priority date	Nov 7, 2011
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

First claim

What is claimed:

1. A method of treating hot flashes in a female subject diagnosed with breast cancer, the method comprising administering to the subject a compound of formula (I)

or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein
each K is independently N or CH, wherein at least two K's are N;
Q, T, U, and V are independently selected from H or R;
W, X, Y and Z are independently selected from H, R, F, Cl, Br, I, OH, OR or CO 2 H;
each R is independently selected from straight chain or branched alkyl groups;
R 1 and R 2 are independently H or R; and
R 3 , R 4 , R 5 and R 6 are independently selected from H or R,
thereby treating hot flashes in the subject.

2. The method of claim 1 , wherein the subject is receiving or has received chemotherapy.

3. The method of claim 1 , wherein the compound is administered concomitant with chemotherapy.

4. The method of claim 1 , wherein the compound is administered after chemotherapy.

5. The method of claim 1 , wherein the compound is administered prior to chemotherapy.

6. The method of claim 1 , wherein administration of the compound is maintained after cessation of the chemotherapy.

7. The method of claim 5 , wherein the subject is due to receive chemotherapy within 10 days or less of receiving the compound.

8. The method of claim 1 , wherein the subject is receiving or has received a hormone replacement or hormone supplement.

9. The method of claim 1 , where the compound is administered in combination with another active agent.

10. The method of claim 1 , wherein the compound is administered in combination with an agonist or antagonist of an estrogen receptor.

11. The method of claim 1 , wherein the compound is administered in combination with tamoxifen.

12. The method of claim 1 , wherein the compound is:

Assignees

• Univ Emory

Inventors

• Natchus Michael G
• Arrendale Richard
• Liotta Dennis
• Desai Ketan
• Shim Hyunsuk

Classifications

• C07C233/75

  with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring · CPC title

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07C233/65

  having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals · CPC title

• C07C229/60

  with amino and carboxyl groups bound in meta- or para- positions · CPC title

• C07C211/27

  having amino groups linked to the six-membered aromatic ring by saturated carbon chains · CPC title